This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (***Currently Amended***) A solid dispersion comprising a poorly soluble bioactive compound dispersed in a polymer matrix that comprises a first polymer comprising a copolymer of vinylpyrrolidone and vinylacetate and a second polymer that has a dissolution profile associated with the creation of a micro-environment enhancing the dissolution of the bioactive compound in an aqueous environment, wherein said first polymer and said second polymer are present in a ratio of ~~about~~ **from** 70:30 to ~~about~~ 80:20 **by weight**.

2. (***Currently Amended***) The solid dispersion according to claim 1 ~~characterized in that the polymer matrix comprises a polymer having~~ **wherein at least one of said first and said second polymers has** a stabilizing effect on the bioactive compound in solution.

3. (***Canceled***)

4. (***Currently Amended***) The solid dispersion according to claim 1 wherein **said second polymer**~~the polymer allowing enhanced dissolution of the bioactive compound in an aqueous environment~~ is a cationic polymer based on dimethylaminoethyl methacrylate and neutral methacrylic ester.

5. (***Currently Amended***) The solid dispersion according to claim 1 wherein ~~the polymer allowing enhanced dissolution of the bioactive compound in an aqueous environment~~ **said second polymer** is hydroxyl-propyl methyl cellulose.

6. (***Canceled***) ~~The solid dispersion according to claim 1 wherein the polymer matrix comprises a cationic polymer based on dimethylaminoethyl methacrylate and neutral methacrylic esters and said first polymer.~~

7. (***Canceled***)

8. (***Canceled***)

9. (***Canceled***) ~~The solid dispersion according to claim 1 enhancing the bioavailability of an orally administered bioactive compound.~~

10. (***Previously Presented***) The solid dispersion according to claim 1 wherein the bioactive compound is a class II drug in the Biopharmaceutical Classification System.

11. (***Previously Presented***) The solid dispersion according to claim 1 wherein the bioactive compound is a class IV drug in the Biopharmaceutical Classification System.

12. (***Previously Presented***) The solid dispersion according to claim 1 wherein the aqueous environment is a gastro-intestinal fluid.

13. (***Previously Presented***) The solid dispersion according to claim 12 wherein the aqueous environment is a gastric fluid.

14. (***Previously Presented***) The solid dispersion according to claim 1 prepared by extrusion.

15. (***Previously Presented***) The solid dispersion according to claim 1 prepared by spray-drying.

16. (***Previously Presented***) A solid dispersion comprising a poorly soluble bioactive compound dispersed in a polymer matrix that comprises a first polymer that allows a homogenous or molecular dispersion of the bioactive compound in the polymer matrix and a second polymer that has a dissolution profile associated with the creation of a micro-environment enhancing the dissolution of the bioactive compound in an aqueous environment, wherein said first polymer and said second polymer are present in a ratio of ~~about~~ 70:30 **by weight**.

17. (***Currently Amended***) The solid dispersion according to claim **[[1]]16** ~~**characterized in that the polymer matrix comprises a polymer having**~~ **wherein at least one of said first and said second polymers has** a stabilizing effect on the bioactive compound in solution.

18. (***Currently Amended***) The solid dispersion according to claim **[[1]]16** wherein the **first** polymer ~~**allowing a homogenous dispersion**~~ is a copolymer of vinylpyrrolidone and vinylacetate.

19. (***Currently Amended***) The solid dispersion according to claim **[[1]]16** wherein the **second** polymer ~~**allowing enhanced dissolution of the bioactive compound in an aqueous environment**~~ is a cationic polymer based on dimethylaminoethyl methacrylate and neutral methacrylic ester.

20. (***Currently Amended***) The solid dispersion according to claim **[[1]]16** wherein **said second polymer**~~**the polymer allowing enhanced dissolution of the bioactive compound in an aqueous environment**~~ is hydroxyl-propyl methyl cellulose.

21. (***Currently Amended***) The solid dispersion according to claim **[[1]]16** wherein the polymer matrix comprises a cationic polymer based on dimethylaminoethyl methacrylate and neutral methacrylic esters and a copolymer of vinylpyrrolidone and vinylacetate.

22. (***Currently Amended***) The solid dispersion according to claim **[[1]]16** wherein the polymer matrix comprises hydroxyl-propyl methyl cellulose and a copolymer of vinylpyrrolidone and vinylacetate.

23. (***Canceled***) ~~The solid dispersion according to claim **[[1]]16** enhancing the bioavailability of an orally administered bioactive compound.~~

24. (***Currently Amended***) The solid dispersion according to claim **[[1]]16** wherein the bioactive compound is a class II drug in the Biopharmaceutical Classification System.

25. (***Currently Amended***) The solid dispersion according to claim **[[1]]<u>16</u>** wherein the bioactive compound is a class IV drug in the Biopharmaceutical Classification System.

26. (***Currently Amended***) The solid dispersion according to claim **[[1]]<u>16</u>** wherein the aqueous environment is a gastro-intestinal fluid.

27. (***Currently Amended***) The solid dispersion according to claim **[[12]]<u>26</u>** wherein the aqueous environment is a gastric fluid.

28. (***Currently Amended***) The solid dispersion according to claim **[[1]]<u>16</u>** prepared by extrusion.

29. (***Currently Amended***) The solid dispersion according to claim **[[1]]<u>16</u>** prepared by spray-drying.